Overall response rate (ORR) is defined as the percentage of patients in a treatment group who have a partial or complete response to therapy over a certain time period. In studies, it helps to measure the cancer-killing properties of a medicine. In the initial review in May 2021, 83% (2...
Despite increased interest in the biomarker field, only a small number of breast cancer biomarkers are known to be clinically useful. Therefore, it is very important to characterise the success rate of biomarkers in this field and study potential reasons for the deficit. We therefore aim to ...
Dennis Slamon, director of the Revlon/UCLA Women's Cancer Research Program and lead investigator of the Kisqali clinical trial, told "Good Morning America." "We found that adding this drug to the best available standard therapy will decrease the recurrence rate by as much as 25%." Editor’...
To find an answer, Parker launched a large-scale research project seven years ago to determine whether the use of predictive biomarkers—which help assess a patient's likely response to a particular treatment—improved the odds that a new cancer drug would be approved inclinical trialsconducted ov...
HealthYatra Medical Value Travel Facilitator in India and abroad. We provide customized health services to our client starting from basic consultation to full medical treatment.
The most effective treatment group was the IUI group, who achieved a 22% live birth rate. The Clomid-only treatment group was 14% and the couples who received no treatment at all had a 17% birth rate, better success than getting treatment. ...
Systemic treatment for hepatocellular carcinoma (HCC) has been boosted by the incorporation of new agents after many negative phase III trials in the decade since the approval of sorafenib. Sorafenib introduced the concept that targeting specific hallmar
Brain Tumor Surgery Success Rate - The surgical removal by and large is the most effective treatment of brain tumor. With early treatment, more than 85% of patients survive for 5 years
The extreme drug resistance (EDR) assay has not been widely studied in the setting of non-metastatic breast cancer. We evaluated the feasibility of performing the assay in 144 primary breast tumor specimens from two institutions by determining the rate of successful tumor culture for assays, number...
It's kind of interesting. The response rate in phase 2 and phase 3 of these two trials was identical and the progression-free survival was nearly identical. I think it was 22 vs 25 months. You have to wonder what the years of effort and expense of this randomized trial really got us....